Access the latest updates including news, publications, activities from FIP and its constituencies, on this page. Discover what happened at FIP this month, explore recent announcements and campaigns, and browse the archived news in case you missed any.
Stay up to date by following us on social media (Facebook, Instagram, LinkedIn, X) and subscribing to our newsletters. Share the news with your networks and help amplify the work of FIP globally.
Transformation of pharmaceutical education, which includes expansion of the number of pharmaceutical education institutions globally and a large shift to online learning, is one of several major current trends in pharmacy identified by the FIP Board of Pharmaceutical Practice.
The findings are presented in the board’s “Trend analysis report amid the COVID-19 pandemic, 2021-2022”, published today. The report contains directions identified by each of FIP’s sections, covering academic pharmacy, clinical biology, health and medicines information, community pharmacy, hospital pharmacy, industrial pharmacy, military and emergency pharmacy, and social and administrative pharmacy. The changes identified have been classed into six major trend groupings as follow:
- Transformation in pharmaceutical education;
- Expanding scope of practice;
- Pandemic and natural disaster preparation;
- Cultural and environmental concerns;
- Increased investment in data systems and automation; and
- Health security, economic and distribution concerns.
“FIP’s most valuable asset is its people: the network of pharmaceutical healthcare experts it brings together. Through their commitment and practice they combine knowledge and adaptability so our profession can navigate the challenges of the present and future, to better serve our communities and healthcare systems. This report, offering insight into each sector of pharmacy practice, can be used as a strategic tool in planning for the developments ahead that will impact on how we work as the world emerges from the COVID-19 pandemic,” said Mr Daragh Connolly, chair, FIP Board of Pharmaceutical Practice.